Aygen, B. Et Al. 2020. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology , vol.31, no.4 , 305-317.

Aygen, B., Demirtürk, N., Yıldız, O., Çelen, M. K., Çelik, İ., Barut, Ş., ... Ural, O.(2020). Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turkish Journal of Gastroenterology , vol.31, no.4, 305-317.

Aygen, Bilgehan Et Al. "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience," Turkish Journal of Gastroenterology , vol.31, no.4, 305-317, 2020

Aygen, Bilgehan Et Al. "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience." Turkish Journal of Gastroenterology , vol.31, no.4, pp.305-317, 2020

Aygen, B. Et Al. (2020) . "Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience." Turkish Journal of Gastroenterology , vol.31, no.4, pp.305-317.

@article{article, author={Bilgehan Aygen Et Al. }, title={Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience}, journal={Turkish Journal of Gastroenterology}, year=2020, pages={305-317} }